Project Grant R01CA308037
Award Date 9/1/26
Completion Date 8/31/29
Dollars Obligated $540K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Los Angeles, CA 90095, USA
Similar Awards
- The National Cancer Institute awarded the University of California, Los Angeles $653,568 on July 1, 2026, through the Cancer Treatment Research program (CFDA 93.395) to conduct research on enhancing antitumor immunity through pharmacologic modulation of T-cell-mediated cytotoxicity. The research addresses a bottleneck in immunotherapy: naturally occurring T cells targeting tumor-associated antigens or neoantigens often exhibit low to intermediate affinity and weak antitumor activity, and...
- The National Cancer Institute awarded The Regents of the University of California, San Francisco $675,009 on August 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop covalent inhibitors targeting RAS Q61 mutations in cancer. The research, a cross-disciplinary collaboration between investigators with expertise in RAS drug discovery and cancer modeling, focuses on developing novel covalent inhibitors of K-RASQ61C, K-RASQ61H, and N-RASQ61X oncoproteins. These mutations...
- The National Cancer Institute awarded the University of California, Los Angeles $528,265 on May 7, 2026, under the Cancer Treatment Research program (CFDA 93.395) to conduct fragment-based drug discovery against oncogenic microRNA precursors using high-throughput crystallography. The funded research targets the precursor structures (pre-miRNAs) of oncogenic microRNAs (oncomirs) that fold into hairpin configurations recognized and cleaved by microRNA processing enzymes. The project performs...
- The National Cancer Institute awarded The Leland Stanford Junior University $149,353 on August 1, 2026, under the Cancer Research Manpower program (CFDA 93.398) to investigate mechanistic pathways through which P53 reactivation can restore tumor suppression in lung adenocarcinoma and identify cooperative drug combinations for improved therapeutic outcomes. The funded research pursues three specific aims: investigating the mechanisms by which P53 reactivation represses KRAS signaling; exploring...
- The National Cancer Institute awarded the University of Hawaii at Manoa $663,930 under the Cancer Biology Research program (CFDA 93.396) on August 1, 2026, to develop and validate novel biomarkers for predicting immunotherapy response in non-small cell lung cancer (NSCLC). The recipient will conduct two primary aims. In Aim 1, the university will create and validate a laboratory test based on an 11-gene expression signature using 200 tissue samples from NSCLC patients prior to immunotherapy...
- The National Cancer Institute, part of the Department of Health and Human Services, awarded the University of Texas Health Science Center at Houston $635,948 on August 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate phospholipase D1 (PLD1) and transferrin receptor 1 (TFR1) as therapeutic targets in chromosome 3q-amplified non-small cell lung cancer. The project will define the mechanisms by which PLD1 promotes NSCLC progression and tumor microenvironment...
- The National Cancer Institute awarded Northwestern University $631,487 under the Cancer Cause and Prevention Research program (CFDA 93.393) on June 1, 2026, to conduct mechanistic research on LKB1-mutant lung cancer and therapeutic resistance. The research combines genomics and mass spectrometry approaches with lung cancer cell lines and mouse models to determine how LKB1 loss regulates HDAC3/NKX2-1 complex function, to test whether LKB1 status predicts response to combined KRAS pathway...
- The National Cancer Institute awarded University of Massachusetts Medical School $1.06 million on July 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to engineer multi-targeted nanoparticle-based immunotherapy for pancreatic cancer. The funded work develops lipid-based nanoparticles (NPs) carrying RAS pathway inhibitors (trametinib, palbociclib, or RMC-7977) and STING/TLR4 innate immune agonists, designed to home specifically to tumor cells and dendritic cells within the...
- The National Institutes of Health National Cancer Institute awarded the University of Southern California $479,234 on May 15, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate nonsense-mediated mRNA decay mechanisms in cancer biology. The project explores how nonsense-mediated mRNA decay (NMD) functions beyond its conventional role of degrading faulty transcripts, with three specific aims: decode gene dependencies in cancer cell lines using NMD residual signatures from...
- The National Institutes of Health National Cancer Institute awarded the University of California, San Diego $771,811 on June 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to identify small molecule activators of type I interferon signaling for cancer treatment. The research focuses on discovering and developing small molecule inhibitors targeting USP18, a ubiquitin protease that suppresses the type I interferon response through negative feedback regulation. Prior work...